Tuesday, November 10, 2026, 1:00 PM-2 PM ET Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET Hear experts discuss a multidisciplinary approach to oncopathology for HER2 assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT,Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.
April 2025—Rebecca Previs, MD, MS, gynecologic oncologist and director of medical affairs at Labcorp, captures the vibe ahead of the ASCO conference next month in Chicago in just a few words. “It’s exciting,” she says. “This is unprecedented territory.” With the field undergoing “a major shift toward biology-driven rather than tissue-of-origin-driven oncology treatment,” Dr. Previs is far from the only industry representative who is optimistic about the future—though the many challenges ahead temper that excitement.
April 2025—Payer policy changes—“It’s almost impossible for the provider community to keep up,” Harley Ross of XiFin said in a Feb. 14 online roundtable led by CAP TODAY publisher Bob McGonnagle. Ross and five other experts in pathology and laboratory medicine billing talked about prior authorizations, denials, narrow networks, and the need to advocate for laboratories.
April 2025—CAP TODAY publisher Bob McGonnagle spoke with Anthony Alburo, MBA, market development manager, diagnostics, Tosoh Bioscience, Melanie Samko, director of marketing, Tosoh Bioscience, and Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare. Anthony Alburo opens the conversation.
Anthony Alburo: Tosoh Bioscience has a longstanding legacy in immunoassay diagnostics and HPLC [high-performance liquid chromatography] technology. Our immunoassay platforms support comprehensive cancer care with reimbursable tests for oncology, endocrinology, reproductive health, and chronic disease management. Our HPLC column solution has set the standard in A1C testing, a key factor in managing diabetes, which can intersect with cancer treatment. We remain committed to advancing laboratory science to support clinicians and patients at every stage of care.
I’m honored to introduce Melanie Samko, our director of marketing, who brings not only a deep expertise in health care marketing but also a deep personal perspective: She is a breast cancer survivor. Her journey highlights the real-world impact of early detection, diagnostic accuracy, and patient advocacy. Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare, which recently merged with the US Oncology Network, has extensive expertise in laboratory operations and compliance. She will provide invaluable insights into the challenges and advancements in oncology diagnostics. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Tosoh Bioscience in recognition of National Cancer Prevention Month.
March 2025—Like an inspired Adam in the Garden of Eden, molecular experts have been busy with the naming process as it applies to liquid biopsy. It’s lost to the myths of time whether Adam revised his nomenclature, but pathologists and other experts are eager to identify new assays as they push this field forward, from circulating cell-free DNA to circulating tumor DNA to circulating tumor RNA. Soon another assay, one that combines ctDNA and ctRNA, could begin to make its mark as well, says Keyur P. Patel, MD, PhD, medical director of the molecular diagnostics laboratory, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center. He and his colleagues plan to launch an assay to look for circulating total nucleic acid. “DNA plus RNA equals TNA—that’s the mathematical equation,” jokes Dr. Patel, who is also professor, Department of Hematopathology, Division of Pathology and Laboratory Medicine. And like that first zookeeper, there’s even an actual beast for experts to name.
March 2025—Theresa Kinard, MD, knew little about phosphatidylethanol (PEth), a blood-based biomarker of alcohol use, when she noticed that patients who adamantly denied drinking were testing positive in their liver pretransplant evaluations.
March 2025—The Ventana CLDN18 (43-14A) RxDx Assay, the companion diagnostic for zolbetuximab, detects the claudin 18 protein in formalin-fixed, paraffin-embedded gastric adenocarcinoma including gastroesophageal junction tissue specimens. Gastric intestinal metaplasia can be used as a positive tissue control and system level control and should display weak to moderate membrane staining.
March 2025—For clinical pathology practice, generative artificial intelligence can open new efficiencies and opportunities, and the authors of an article published in Archives of Pathology & Laboratory Medicine set out how it can be used and its risks.
March 2025—I’ve worked in the past with employers that were wholly or majority owned by private equity firms, and the ethos is conspicuously different from that in which ownership is by medical professionals (either MD or MHA), in that it’s all about the bottom line. We can all acknowledge that efficiencies are necessary in American health care, but the core of its ethos must never be questioned; it’s ultimately all about the patient. A situation has arisen in my home state of Connecticut that should alarm anyone interested in health care—the decimation of three fine hospitals by private equity mismanagement, a history that reads sadly like a forensic investigation.
March 2025—A study of oncology patients at the Medical College of Wisconsin sheds light on how they perceive the content and timing of pathology report review. The study findings were gathered through in-person and telehealth interviews with patients with breast, endocrine, gastrointestinal, genitourinary, and thoracic malignancies. Medical student Amber Y. Bo, MD, in 2022 and 2023 conducted 230 interviews with patients who had a prior opportunity to review their reports in the patient portal.
March 2025—Revised requirements in the 2024 edition of the CAP accreditation all common and laboratory general checklists address the activity menu, alternative performance assessment, the quality management system, and infectious disease reporting, among other things. “When we make revisions in the requirements, we do it for good reason,” says Stephen J. Sarewitz, MD, advisor to and immediate past chair of the CAP Checklists Committee. “In many cases it is to clarify something that was unclear” and raised questions. “In other cases, a change addresses an area in which laboratories get deficiencies, which we are trying to prevent. We also want to reflect state-of-the-art laboratory medicine. As it advances, the checklists are revised accordingly.”
